Go Deep
Kyntra Bio, Inc.
Kyntra Bio, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | -18,580 | -0.7 | -0.72 | 0.00 | 507.67 |
| Oct 2026 | -18,327 | -0.6 | -0.65 | 0.00 | 459.37 |
| Oct 2026 | -20,341 | -0.7 | -0.71 | 0.00 | 500.63 |
| Oct 2026 | -20,341 | -0.7 | -0.71 | 0.00 | 500.63 |
| Oct 2026 | -20,306 | -0.7 | -0.70 | 0.00 | 492.77 |
| Oct 2026 | -20,362 | -0.7 | -0.70 | 0.00 | 492.72 |
Kyntra Bio, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | -1,474,000.0 | 3,738,000.0 | 1,277,000.0 | 1,076,000.0 |
| Net Profit | 11,974,000.0 | -15,198,000.0 | -14,220,000.0 | 200,636,000.0 |
| EPS | 3.0 | -3.8 | -3.5 | 49.6 |
Kyntra Bio, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 6,440,000.0 | 29,621,000.0 | 46,803,000.0 | 140,734,000.0 | — |
| Net Profit | 183,452,000.0 | -47,579,000.0 | -284,232,000.0 | -293,654,000.0 | — |
| EPS | 45.4 | -12.0 | -73.0 | -78.5 | — |
Kyntra Bio, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 119,594,000.0 | 214,525,000.0 | 423,529,000.0 | 610,087,000.0 | — |
| Total Liabilities | 115,119,000.0 | 398,160,000.0 | 585,728,000.0 | 611,567,000.0 | — |
| Total Equity | -30,038,000.0 | -225,602,000.0 | -204,166,000.0 | -21,447,000.0 | — |
Owes vs Owns
Kyntra Bio, Inc. owed $1.08 for every $1 it owned in Jun 2026, up from $1.00 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 1.08× | 0.96× | 1.86× | 1.38× | 1.00× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Kyntra Bio, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 74.4%Receivables 3.5%Inventory 3.1%Long-term investments 16.9%Other assets 2.1%
How it's funded — Dec 2025
Payables 3.1%Other liabilities 93.1%Shareholders' equity 3.7%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 89.0 | 50.5 | 203.5 | 422.0 |
| Receivables | 4.2 | 29.0 | 33.6 | 16.3 |
| Inventory | 3.7 | 3.2 | 17.2 | 40.4 |
| Fixed assets (tangible) | 0.0 | 0.0 | 69.7 | 100.5 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 20.2 | 0.0 | 5.3 | 9.4 |
| Other assets | 2.5 | 131.9 | 94.3 | 21.4 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 0.0 | 12.6 | 10.3 |
| Long-term debt | 0.0 | 73.1 | 71.9 | 79.6 |
| Payables | 3.7 | 5.1 | 15.8 | 30.8 |
| Other liabilities | 111.4 | 320.0 | 485.4 | 490.9 |
| Shareholders' equity | 4.5 | -183.6 | -162.2 | -1.5 |
| Net tangible assets | -30.0 | -225.6 | -204.2 | -21.4 |
Kyntra Bio, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -4,774,000.0 | -137,999,000.0 | -315,021,000.0 | -145,933,000.0 | — |
| Investing Activities | 35,419,000.0 | 125,993,000.0 | 153,657,000.0 | 89,116,000.0 | — |
| Financing Activities | -86,028,000.0 | -255,000.0 | 122,749,000.0 | 46,776,000.0 | — |